Amanda's Story: Changing the Odds by Inspiring Open Conversations on Cancer

Health issues like cancer were rarely discussed in Amanda's family. Determined to "Change the Odds" against cancer for communities like her small town in Texas, she's breaking the silence and inspiring others to have open conversations about cancer risk and be proactive with their health. Hosted by actor and cancer community advocate, Patrick Dempsey.

Health Answers by Pfizer

Health Answers by Pfizer is a consumer digital experience powered by generative artificial intelligence that allows you to ask your biggest and smallest health and wellness questions - anytime, anywhere - and receive real-time, relevant responses and next steps.

The Future of IBD Care: Pfizer Leads a New Era of Noninvasive Monitoring

At Pfizer, we are committed to improving care and addressing inequities for patients living with inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease.

Protecting Patients: Counterfeit Drugs in Oncology and the Fight Against Them

Despite strides made in oncology, the rise of counterfeit drugs poses an increasingly urgent challenge around the globe. Pfizer spoke to OncLive to share our mission to combat counterfeit drugs and educate oncologists on how to protect patients.

Three Steps to Boost Your Health Through Nutrition

Pfizer is dedicated to improving healthcare for people all over the globe. Sometimes that means developing a new medication or making a scientific breakthrough, and sometimes it's as simple as educating and empowering people to make better decisions.

Connected. Active. Involved.

Welcome to the official website for retirees of Pfizer and its legacy organizations.

Pfizer News

Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance
April 29, 2025
Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
April 26, 2025
Pfizer Announces 2025 Shareholder Meeting Preliminary Results
April 24, 2025
Pfizer Declares Second-Quarter 2025 Dividend
April 23, 2025
Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting
April 23, 2025
ACIP Votes to Expand Recommendation for Pfizer's RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
April 16, 2025
Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron
April 14, 2025
Pfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24
April 10, 2025
European Commission Approves Pfizer's RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
April 01, 2025
Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts
March 18, 2025
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
March 11, 2025
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
February 24, 2025
Pfizer's TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
February 13, 2025
U.S. FDA Approves Pfizer's ADCETRIS® Combination Regimen for the treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
February 12, 2025
Pfizer and Astellas' PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
February 10, 2025
Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance
February 04, 2025
Pfizer's BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
February 03, 2025
Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium
January 28, 2025
Pfizer's BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
January 25, 2025
Pfizer's Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-NaÏve, High-Risk Non-Muscle Invasive Bladder Cancer
January 10, 2025
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
January 06, 2025
U.S. FDA Approves Pfizer's BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
December 20, 2024
Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts
December 19, 2024
Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance
December 17, 2024
Pfizer Declares First-Quarter 2025 Dividend
December 12, 2024
Pfizer's IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer
December 12, 2024
Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance
December 10, 2024
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium
December 10, 2024
Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS
December 05, 2024

Click here to view all Pfizer News stories.

Join the Pfizer Plus Community Corner

When you join the PfizerPlus.com community, you can get access to our special “member’s only” features including:

  • Member Only Content
  • Email Updates
  • PfizerPlus.com Community